This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Dabbs, E. R.
Right arrow Articles by Nikitina, N.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Dabbs, E. R.
Right arrow Articles by Nikitina, N.

 Previous Article  |  Next Article 

Antimicrobial Agents and Chemotherapy, April 2003, p. 1476-1478, Vol. 47, No. 4
0066-4804/03/$08.00+0     DOI: 10.1128/AAC.47.4.1476-1478.2003
Copyright © 2003, American Society for Microbiology. All Rights Reserved.

Pathogenic Nocardia, Rhodococcus, and Related Organisms Are Highly Susceptible to Imidazole Antifungals

Eric R. Dabbs,* Samantha Naidoo, Catherine Lephoto, and Natalya Nikitina

School of Molecular and Cell Biology, University of the Witwatersrand, Johannesburg, South Africa

Received 8 May 2002/ Returned for modification 3 July 2002/ Accepted 27 January 2003


arrow
ABSTRACT
 
Rhodococcus equi and species of Nocardia and Gordonia may be human opportunistic pathogens. We find that these, as well as several isolates from closely related genera, are highly susceptible to the imidazoles bifonazole, clotrimazole, econazole, and miconazole, whose MICs are <=1 µg/ml. In liquid cultures 1 µg of the drug/ml was bacteriostatic and 10 µg/ml was bactericidal. On solid media at 10 µg of azole/ml no resistant mutants could be isolated. An MIC of 1 to 15 µg/ml was observed with ketoconazole, whereas none of these organisms was inhibited by the triazoles fluconazole and voriconazole (100 µg/ml). Imidazoles may offer the prospect of treatment of nocardioform mycetomas and may provide the basis for the development of additional antimicrobial agents to combat these pathogens.


arrow
TEXT
 
There has been an increase in the number of individuals infected with opportunistic pathogens of the nocardioform group of bacteria as a result of the susceptibility of AIDS patients and some other categories of immunocompromised patients (1, 4, 9). The soilborne organism Rhodococcus equi may cause chronic and severe pyogranulomatous pneumonia in foals, and similar symptoms can arise in humans with weakened immune systems; subsequent dissemination from the lung to other body sites sometimes also occurs in either horses or humans (10). Nocardia brasiliensis is a common cause of localized chronic mycetoma in Africa and other tropical areas and may develop into a disseminated infection in immunocompromised individuals (16, 20, 21). Nocardia otitidiscaviarum (3), Dietzia maris (2, 17), Gordonia bronchialis, Gordonia rubripertincta (18), and Mycobacterium vaccae (8) may also infect humans. Increasing incidence of drug resistance and multiple resistance for all main classes of antibiotics in both R. equi (11, 15) and N. brasiliensis (25) makes it desirable to identify additional antibacterial agents, preferably targeting novel elements in the prokaryotic cell to minimize the likelihood of cross-resistance from familiar antibiotics. Antifungal azoles act on organisms such as Candida albicans by blocking a step in the synthesis of ergosterol, resulting in damage to membrane integrity. They are selective inhibitors of the cytochrome P450-dependent 14-{alpha} demethylation of lanosterol but have very little effect on mammalian cytochrome P450 (26). The specificity of their mode of action suggests that susceptibility in bacteria is unlikely; however, they inhibit Helicobacter pylori at a concentration of 2 to 64 µg/ml (24). In earlier work miconazole and ketoconazole were shown to inhibit Staphylococcus aureus (22). Metronidazole and other nitroimidazoles are bactericidal against H. pylori through toxic metabolites that cause DNA strand breakage (14). Recently miconazole and clotrimazole have been shown to have in vitro activity against Mycobacterium tuberculosis, the MIC being 2 to 5 µg/ml (23). Here we show that nocardioform opportunistic pathogens and other related strains from seven genera are highly susceptible to bifonazole and econazole as well as to miconazole and clotrimazole. However, fluconazole and the newly developed voriconazole (19) showed no inhibitory effects on any of these organisms.

Strains used in this work are listed in Table 1. Cultures were grown on brain heart infusion (BHI; pH 7.4), Luria-Bertani (pH 7.0), or Sabouraud dextrose (SD; 4%, pH 5.6) media solidified where required with 1.5% agar. The nonionic detergent Tween 80 was added to a final concentration of 0.7% to reduce aggregation during optical density (OD) and CFU measurements of cultures. All incubations were at 30°C. Bifonazole, clotrimazole, econazole, and miconazole were purchased from Sigma Chemical Co. Fluconazole and voriconazole were kindly provided by Pfizer Inc. Solid medium MICs were measured by replicating ~104 CFU onto plates supplemented with 0.25, 0.5, 1.0, 2.0, 5.0, 10, 20, 50, or 100 µg of drug/ml, followed by further intermediate concentrations where necessary. MICs in liquid BHI medium (10 ml, with five 5-mm glass beads to promote dispersal) were measured by monitoring the effect of drug challenge on viable counts and on OD at 600 nm with a Milton Roy Spectronic 601 spectrophotometer.


View this table:
[in this window]
[in a new window]
  		TABLE 1. Susceptibility of bacterial strains to antifungal drugsa

On BHI solid medium the MIC of each of the four azoles for R. equi strain ATCC 14887 was <=1 µg/ml; the MIC for N. brasiliensis was 0.5 to 1.0 µg/ml (Table 1). The least susceptibility, an MIC of 2 µg/ml, was observed for M. vaccae with bifonazole. Ketoconazole, an orally administered imidazole, was less effective: most MICs were ~10 µg/ml. Fluconazole and voriconazole showed no inhibitory effects in these experiments. We included 4-nitroimidazole in our testing since the MIC for M. tuberculosis has been reported to be ~20 µg/ml, but no inhibitory effect was observed at 100 µg/ml. H. pylori is highly susceptible to metronidazole (14), but this compound did not affect the growth of the strains we investigated. Azole MICs were not medium dependent: MICs on BHI medium were similar to those on Luria-Bertani or SD medium. Comparison with fungi on SD plates showed that these bacterial strains were in every case inhibited at lower drug concentrations than those at which the fungal strains were inhibited; for example, the econazole MICs were 5 µg/ml for C. albicans, 2 µg/ml for Fusarium sp., and 3 µg/ml for Saccharomyces cerevisiae and Aspergillus niger. Fluconazole and voriconazole had MICs similar to or lower than these values against the fungal strains. Nystatin also targets ergosterol and interferes with fungal membrane integrity. However, instead of blocking synthesis this polyene binds to the ergosterol, leading to formation of a pore, allowing leakage of intracellular fungal ions and macromolecules (5). We tested the effect of nystatin on these bacterial strains, but no inhibition was observed, suggesting limits to comparability between azole action on prokaryotic nocardioforms and eukaryotic fungi.

The efficacy of antimicrobial chemotherapy is greatly diminished in the face of selection of resistant mutants: the average mutation rate in M. tuberculosis for resistance to isoniazid is 1 in 10-5 to 1 in 10-6; the corresponding figures for rifampin and ethambutol are 1 in 10-8 and 1 in 10-4, respectively (12). We attempted to select mutants resistant to 10 µg of each of the four imidazoles/ml; approximately 1 x 109 CFU of M. vaccae, 1 x 109 CFU of N. brasiliensis, or 4 x 109 CFU of R. equi in BHI broth were challenged with each of the antifungals, but no clones resistant to this level of drug were obtained. Similar results were obtained from cultures spread on BHI plates. These experiments were repeated four or more times, indicating that resistance to these compounds arises extremely rarely. At concentrations about 10 times the MIC the imidazoles were bactericidal (Fig. 1).



View larger version (18K):
[in this window]
[in a new window]
  		FIG. 1. Response to clotrimazole (10 µg/ml) challenge for cultures of R. equi ATCC 14887 (A) and D. maris JCM 6166 (B) in the presence (+) or absence (-) of an imidazole. The drug was added at 12 h (third data point). The scales of the y axes are logarithmic.

Recently a sterol biosynthetic pathway has been identified in mycobacteria (13) and the putative target was identified (7). Our results suggest that this pathway is present in nocardioform bacteria too. The drugs we determined to be bactericidal at low concentrations are for topical rather than systemic use (6), so they might be tested against mycetomas, infections of the skin and subcutaneous tissue by Nocardia and related organisms Actinomadura madurae and Streptomyces somaliensis (16). Since antifungal imidazoles are routinely used on humans, their pharmacology is well established. Thus there is a realistic potential for their use in treatment of infections by these opportunistic pathogens.


arrow
ACKNOWLEDGMENTS
 
We thank Y. Mikami for helpful discussions and providing strains. We are indebted to Pfizer Laboratories Ltd. for generously supplying voriconazole and fluconazole.

This work was supported by a grant from the Medical Research Council of South Africa.


arrow
FOOTNOTES
 
* Corresponding author. Mailing address: School of Molecular and Cell Biology, University of the Witwatersrand, Johannesburg P O WITS 2050, South Africa. Phone: 27 11 717 6364. Fax: 27 11 403 1733. E-mail: dabbse{at}gecko.biol.wits.ac.za. Back


arrow
REFERENCES
 
    1
  1. Akan, H., M. Akova, H. Ataoglu, G. Aksu, O. Arslan, and H. Koc. 1998. Rhodococcus equi and Nocardia brasiliensis infection of the brain and liver in a patient with acute nonlymphoblastic leukemia. Eur. J. Clin. Microbiol. Infect. Dis. 17:737-739.[CrossRef][Medline]
    2. 2
  2. Bemer-Melchior, P., A. Haloun, P. Riegel, and H. B. Drugeon. 1998. Bacteremia due to Dietzia maris in an immunocompromised patient. Clin. Infect. Dis. 29:1340-1341.
    3. 3
  3. Clark, N. M., D. K. Braun, A. Pasternak, and C. E. Chenoweth. 1995. Primary cutaneous Nocardia otitidiscaviarum infection: case report and review. Clin. Infect. Dis. 20:1266-1270.[Medline]
    4. 4
  4. Clotet, B., G. Sierra, and A. Erice. 1993. Rhodococcus equi infection in HIV-infected patients. J. Acquir. Immune Defic. Syndr. 6:429-430.
    5. 5
  5. Finkelstein, A., and R. Holz. 1973. Aqueous pores created in thin lipid membranes by the polyene antibiotics nystatin and amphotericin B. Membranes 2:377-408.[Medline]
    6. 6
  6. Georgopapadakou, N. H., and T. J. Walsh. 1996. Antifungal agents: chemotherapeutic targets and immunological strategies. Antimicrob. Agents Chemother. 40:279-291.[Medline]
    7. 7
  7. Guardiola-Diaz, H. M., L. A. Foster, D. Mushrush, and A. D. Vaz. 2001. Azole-antifungal binding to a novel cytochrome P450 from Mycobacterium tuberculosis: implications for treatment of tuberculosis. Biochem. Pharmacol. 61:1463-1470.[CrossRef][Medline]
    8. 8
  8. Hachem, R., I. Raad, K. V. Rolston, E. Whimbey, R. Katz, J. Tarrand, and H Libshitz. 1996. Cutaneous and pulmonary infections caused by Mycobacterium vaccae. Clin. Infect. Dis. 23:173-175.[Medline]
    9. 9
  9. Harvey, R. L., and J. C. Sunstrum. 1991. Rhodococcus equi infection in patients with and without human immunodeficiency virus infection. Rev. Infect. Dis. 13:139-145.[Medline]
    10. 10
  10. Hondalus, M. K. 1997. Pathogenesis and virulence of Rhodococcus equi. Vet. Microbiol. 56:257-268.[CrossRef][Medline]
    11. 11
  11. Hsueh, P. R., C. C. Hung, L. J. Teng, M. C. Yu, Y. C. Chen, H. K. Wang, and K. T. Luh. 1998. Report of invasive Rhodococcus equi infections in Taiwan, with an emphasis on the emergence of multidrug-resistant strains. Clin. Infect. Dis. 27:370-375.[Medline]
    12. 12
  12. Irwin, L. L., and L. S. Rickman. 1995. New, unfamiliar drugs for suspected drug-resistant tuberculosis. Infect. Med. 12:32-39.
    13. 13
  13. Jackson, C. J., D. C. Lamb, D. E. Kelly, and S. L. Kelly. 2000. Bactericidal and inhibitory effects of azole antifungal compounds on Mycobacterium smegmatis. FEMS Microbiol. Lett. 192:159-162.[CrossRef][Medline]
    14. 14
  14. Lamp, K. C., C. D. Freeman, N. E. Klutman, and M. K. Lacy. 1999. Pharmacokinetics and pharmacodynamics of the nitroimidazole antimicrobials. Clin. Pharmacokinet. 36:353-373.[CrossRef][Medline]
    15. 15
  15. Nordmann, P., E. Rouveix, M. Guenounou, and M. H. Nicolas. 1992. Pulmonary abscess due to a rifampin and fluoroquinolone resistant Rhodococcus equi strain in a HIV infected patient. Eur. J. Clin. Microbiol. Infect. Dis. 11:557-558.[CrossRef][Medline]
    16. 16
  16. Palestine, R. F., and R. S. Rogers. 1982. Diagnosis and treatment of mycetoma. J. Am. Acad. Dermatol. 6:107-111.[Medline]
    17. 17
  17. Pidoux, O., J. N. Argenson, V. Jacomo, and M. Drancourt. 2001. Molecular identification of a Dietzia maris hip prosthesis infection isolate. J. Clin. Microbiol. 39:2634-2636.[Abstract/Free Full Text]
    18. 18
  18. Richet, H. M., P. C. Craven, J. M. Brown, B. A. Lasker, C. D. Cox, M. M. McNeil, A. D. Tice, W. R. Jarvis, and O. C. Tablan. 1991. A cluster of Rhodococcus (Gordona) bronchialis sternal-wound infections after coronary-artery bypass surgery. N. Engl. J. Med. 324:104-109.[Medline]
    19. 19
  19. Sabo, J. A., and S. M. Abdel-Rahman. 2000. Voriconazole: a new triazole antifungal. Ann. Pharmacother. 34:1032-1043.[Abstract]
    20. 20
  20. Salinas-Carmona, M. C. 2000. Nocardia brasiliensis: from microbe to human and experimental infections. Microbes Infect. 2:1373-1381.[CrossRef][Medline]
    21. 21
  21. Sarzier, J. S., J. N. Greene, R. L. Sandin, A. S. Spiers, P. J. Emmanuel, R. E. Valder, M. E. Gombert, and A. L. Vincent. 1998. Disseminated Nocardia brasiliensis infection in an immuno-compromised patient. Cancer Control 5:64-67.[Medline]
    22. 22
  22. Sud, I. J., and D. S. Feingold. 1982. Action of antifungal imidazoles on Staphylococcus aureus. Antimicrob. Agents Chemother. 22:470-474.[Abstract/Free Full Text]
    23. 23
  23. Sun, Z., and Y. Zhang. 1999. Antituberculosis activity of certain antifungal and antihelmintic drugs. Tuber. Lung Dis. 79:319-320.[CrossRef][Medline]
    24. 24
  24. von Recklinghausen, G., C. Di Maio, and R. Ansorg. 1993. Activity of antibiotics and azole antimycotics against Helicobacter pylori. Zentbl. Bakteriol. 280:279-285.
    25. 25
  25. Yazawa, K., Y. Mikami, A. Maeda, M. Akao, N. Morisaki, and S. Iwasaki. 1993. Inactivation of rifampin by Nocardia brasiliensis. Antimicrob. Agents Chemother. 37:1313-1317.[Abstract/Free Full Text]
    26. 26
  26. Yoshida, Y. 1988. Cytochrome P450 of fungi: primary target for azole antifungal agents. Curr. Top. Med. Mycol. 2:388-418.[Medline]

Antimicrobial Agents and Chemotherapy, April 2003, p. 1476-1478, Vol. 47, No. 4
0066-4804/03/$08.00+0     DOI: 10.1128/AAC.47.4.1476-1478.2003
Copyright © 2003, American Society for Microbiology. All Rights Reserved.



This article has been cited by other articles:

  • Helmick, R. A., Fletcher, A. E., Gardner, A. M., Gessner, C. R., Hvitved, A. N., Gustin, M. C., Gardner, P. R. (2005). Imidazole Antibiotics Inhibit the Nitric Oxide Dioxygenase Function of Microbial Flavohemoglobin. Antimicrob. Agents Chemother. 49: 1837-1843 [Abstract] [Full Text]  

This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Dabbs, E. R.
Right arrow Articles by Nikitina, N.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Dabbs, E. R.
Right arrow Articles by Nikitina, N.

Copyright © 2009 by the American Society for Microbiology.   For an alternate route to Journals.ASM.org, visit: http://intl-journals.asm.org | More Info»